EsoCap AG announced the presentation of data showing that for the first time, long-lasting topical drug therapy in the esophagus is possible with the EsoCap smart delivery technology in the upper gastrointestinal tract.
The University of Greifswald conducted an imaging study in twelve healthy volunteers to investigate the disposition of thin films in the esophagus. The imaging study confirmed the excellent functionality of the EsoCap system. This drug delivery system allows a long contact time of the mucoadhesive polymer with the esophageal mucosa. Using a questionnaire completed by the twelve healthy volunteers, the study demonstrated the good swallowability and acceptability of the EsoCap system. 1 The data were presented at the 4th European Conference on Pharmacy, held March 20-21, 2023, in Marseille, France.
“We are in an extremely exciting time in the field of drug delivery,” said Prof. Werner Weitschies, head of the Department of Biopharmacy at the Center for Drug Absorption and Transport at the University of Greifswald. “Until now, local treatment of esophageal diseases has been very difficult due to the extremely short transit time in the esophagus. With the thin film study in healthy volunteers, we were able to visualize the uniform disposition of thin films in vivo.”
“The work performed in Greifswald makes it possible to consider completely new treatment options for esophageal diseases,” said Isabelle Racamier, CEO of EsoCap AG. “EsoCap AG is currently conducting the ACESO randomized, placebo-controlled, double-blind phase II study in eosinophilic esophagitis (EoE).”
